Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 0: clinchem.2004.035832v1, 2004; 10.1373/clinchem.2004.035832
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2004.035832v1
50/11/2125    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Van Meensel, B.
Right arrow Articles by Bossuyt, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van Meensel, B.
Right arrow Articles by Bossuyt, X.

Received on April 19, 2004
Accepted on August 26, 2004

Clinical Immunology

Diagnostic Accuracy of Ten Second-Generation (Human) Tissue Transglutaminase Antibody Assays in Celiac Disease

Britta Van Meensel 1, Martin Hiele 2, Ilse Hoffman 3, Severine Vermeire 2, Paul Rutgeerts 2, Karel Geboes 4, Xavier Bossuyt 1*

1 Laboratory Medicine, Immunology, University Hospital, Leuven, Belgium
2 Internal Medicine, Gastroenterology, University Hospital, Leuven, Belgium
3 Department of Paediatrics, University Hospital, Leuven, Belgium
4 Department of Pathology, University Hospital, Leuven, Belgium

* To whom correspondence should be addressed. E-mail: Xavier.Bossuyt{at}uz.kuleuven.ac.be.

Background: Anti-tissue transglutaminase (tTG) assays that use human tTG as antigen have recently become available. We evaluated commercially available assays with human tTG antigen to estimate their diagnostic accuracies and to determine whether they agree sufficiently to be used interchangeably.

Methods: Ten commercially available second-generation anti-tTG assays were evaluated. The following populations were studied: celiac disease (CD) patients at the time of diagnosis without (n = 70) or with (n = 5) IgA deficiency; diseased controls (n = 70); and CD patients without (n = 28) or with (n = 2) IgA deficiency during follow-up. All individuals included in the study underwent intestinal biopsy. Technical performance (linearity, interference, precision, correlation, and agreement) and diagnostic accuracy (sensitivity and specificity) were compared. Anti-gliadin and anti-endomysium antibodies were also measured.

Results: IgA anti-tTG results correlated well overall, but numerical values differed. Diagnostic sensitivity ranged between 91% and 97% and specificity between 96% and 100%. These were higher than the sensitivity and specificity of the IgA endomysium assay and the IgA gliadin assay. Generally, IgG anti-tTG was less sensitive but more specific than IgG anti-gliadin for the diagnosis of CD in the small group of IgA-deficient patients.

Conclusions: Overall diagnostic performance of IgA tTG assays is acceptable and comparable among the different assays, but numerical values differ. Standardization is needed.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2004 by the American Association for Clinical Chemistry.